Public Summary Document – November 2014 PBAC Meeting 7.1 AFLIBERCEPT 4 mg 0.1 mL injection, 1 x 0.1 mL vial, - Ranibizumab - Document - PDFSEARCH.IO

First Page	Meta Content
	Public Summary Document – November 2014 PBAC Meeting 7.1 AFLIBERCEPT 4 mg/0.1 mL injection, 1 x 0.1 mL vial, Add to Reading List Document Date: 2015-03-16 01:05:14 Open Document File Size: 850,42 KB Share Result on Facebook City Campochiaro / Trial / Meeting Trial / / Company ESC / Regeneron Pharmaceuticals Inc. / Brown / AMD / GE / Bayer Australia Ltd. / / Event FDA Phase / / Facility Consumer Comments facility / / IndustryTerm telephone application / / MedicalCondition macular edema / central retinal vein occlusion / macular degeneration / diabetic retinopathy study / retinal vein occlusion / / Organization Congress / Department of Human Services / PBAC Meeting Administrative Advice Authority / Complex Drugs Unit / Department of Human Services Prior Written Approval of Complex Drugs Reply Paid / Medicare / / Person Used Used / / / Position author / Governor / model / Chief Executive / Dental Medical Practitioners Midwives Nurse / General / / Product Phase-3 / Intravitreal Aflibercept Injection / Intravitreal / / ProvinceOrState Virginia / Pennsylvania / / PublishedMedium Ophthalmology / British Journal of Ophthalmology / / Technology tomography / / URL www.humanservices.gov.au / / SocialTag Ranibizumab Vascular endothelial growth factor Bevacizumab Macular edema Central retinal vein occlusion Macular degeneration Diabetic retinopathy Macula of retina Central retinal vein Ophthalmology

Public Summary Document – November 2014 PBAC Meeting 7.1 AFLIBERCEPT 4 mg/0.1 mL injection, 1 x 0.1 mL vial,Add to Reading List